[go: up one dir, main page]

US20110158933A1 - Liver function and treatment of liver disease - Google Patents

Liver function and treatment of liver disease Download PDF

Info

Publication number
US20110158933A1
US20110158933A1 US12/908,185 US90818510A US2011158933A1 US 20110158933 A1 US20110158933 A1 US 20110158933A1 US 90818510 A US90818510 A US 90818510A US 2011158933 A1 US2011158933 A1 US 2011158933A1
Authority
US
United States
Prior art keywords
liver
bonding
monomer units
alkoxyl
sample
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US12/908,185
Other languages
English (en)
Inventor
Shau-Feng Chang
Chun-Hsien Ma
Kuo-Yi Yang
Chien-Tung Lin
Shyh-Horng Lin
Kai-Wen Huang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Industrial Technology Research Institute ITRI
Original Assignee
Industrial Technology Research Institute ITRI
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Industrial Technology Research Institute ITRI filed Critical Industrial Technology Research Institute ITRI
Assigned to INDUSTRIAL TECHNOLOGY RESEARCH INSTITUTE (ITRI) reassignment INDUSTRIAL TECHNOLOGY RESEARCH INSTITUTE (ITRI) ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: CHANG, SHAU-FENG, HUANG, Kai-wen, LIN, CHIEN-TUNG, LIN, SHYH-HORNG, MA, CHUN-HSIEN, YANG, KUO-YI
Publication of US20110158933A1 publication Critical patent/US20110158933A1/en
Priority to US14/574,036 priority Critical patent/US9474735B2/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/765—Polymers containing oxygen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics

Definitions

  • the liver a vital organ, plays a major role in metabolism of breaking down or modifying toxic substances. It also performs other important function, e.g., glycogen storage, hormone production, plasma protein synthesis, and red blood cell decomposition.
  • liver fibrosis liver cirrhosis
  • liver inflammation liver viral infection
  • liver cancer liver cancer
  • One aspect of this invention relates to a method of improving liver function by administering to a subject in need thereof a pharmaceutical composition obtained by mixing a pharmaceutically acceptable carrier and an isolated preparation containing 20% or higher by weight one or more polymeric compounds each derived from two or more monomer units having Formula (I):
  • each of R 1 and R 2 independently, is H, alkyl, or acyl; each of R 3 , R 4 , R 5 , R 6 , and R 7 , independently, is H, OH, alkoxyl, or acyl; and R 8 is H or a saccharide moiety.
  • the monomer units in the polymeric compound may have one or more of the following features: R 1 and R 2 , independently, is H, each of R 3 and R 7 is H, and each of R 4 , R 5 , and R 6 is OH or alkoxyl, and R 8 is H.
  • monomer units may be covalently linked to each other via bonding between any two atoms of different monomer units, e.g., C4-C8 bonding (i.e., bonding formed between the C4 carbon of one monomer unit and the C8 carbon of the other monomer unit), C4-C6 bonding (i.e., bonding formed between the C4 carbon of one monomer unit and the C6 carbon of the other monomer unit), or C2-O7 (i.e., bonding formed between the C2 carbon of one monomer unit and the O7 oxygen of the other monomer unit).
  • C4-C8 bonding i.e., bonding formed between the C4 carbon of one monomer unit and the C8 carbon of the other monomer unit
  • C4-C6 bonding i.e., bonding formed between the C4 carbon of one monomer unit and the C6 carbon of the other monomer unit
  • C2-O7 i.e., bonding formed between the C2 carbon of one monomer unit and the O7 oxygen of
  • isolated preparation refers to a composition containing one or more of the above-described polymeric compounds that has been partitioned from the natural source or the synthesis mixture.
  • alkyl refers to a straight or branched hydrocarbon, containing 1-10 carbon atoms.
  • alkyl groups include, but are not limited to, methyl, ethyl, n-propyl, i-propyl, n-butyl, i-butyl, and t-butyl.
  • acyl refers to a —C(O)-alkyl or —C(O)-aryl radical. Examples of acyl groups include, but are not limited to, —C(O)—CH 3 and —C(O)-ph.
  • alkoxy refers to an —O-alkyl radical. Examples of alkoxy groups include, but are not limited to, —OCH 3 and —OCH 2 CH 3 .
  • Alkyl mentioned herein can be either substituted or unsubstituted.
  • substituents include, but are not limited to, halo, hydroxyl, amino, cyano, nitro, mercapto, alkoxycarbonyl, amido, carboxy, alkanesulfonyl, alkylcarbonyl, carbamido, carbamyl, carboxyl, thioureido, thiocyanato, sulfonamido, alkyl, alkenyl, alkynyl, alkyloxy, aryl, heteroaryl, cyclyl, heterocyclyl, in which alkyl, alkenyl, alkynyl, alkyloxy, aryl, heteroaryl cyclyl, and heterocyclyl are optionally further substituted with alkyl, aryl, heteroaryl, halogen, hydroxyl, amino, mercapto, cyano, or nitro.
  • saccharide moiety refers to a carbohydrate radical. It can be a radical of monosaccharide (e.g., allose, altrose, glucose, mannose, gulose, idose, galactose, talose, ribuose, psicose, fructose, sorbose, or tagatose), disaccharide (e.g., sucrose, lactulose, lactose, maltose, trehalose, or cellobiose), oligosaccharide (containing 3-10 monosaccharides), or polysaccharide (containing more than 10 monosaccharides).
  • monosaccharide e.g., allose, altrose, glucose, mannose, gulose, idose, galactose, talose, ribuose, psicose, fructose, sorbose, or tagatose
  • disaccharide e.g.
  • the polymeric compounds described above include the compounds themselves, as well as their salts, prodrugs, and solvates, if applicable.
  • a salt for example, can be formed between an anion and a positively charged group (e.g., ammonium ion) on a polymeric compound.
  • Suitable anions include chloride, bromide, iodide, sulfate, nitrate, phosphate, citrate, methanesulfonate, trifluoroacetate, acetate, succinate, malate, tosylate, tartrate, fumurate, glutamate, glucuronate, lactate, glutarate, and maleate.
  • a salt can also be formed between a cation and a negatively charged group (e.g., phenolate or carboxylate) on a polymeric compound.
  • Suitable cations include sodium ion, potassium ion, magnesium ion, calcium ion, and an ammonium cation.
  • the compounds may also be in prodrug and solvate form.
  • prodrugs include esters and other pharmaceutically acceptable derivatives, which, upon administration to a subject, are capable of providing active compounds.
  • a solvate refers to a complex formed between an active compound and a pharmaceutically acceptable solvent.
  • pharmaceutically acceptable solvents include water, ethanol, isopropanol, ethyl acetate, acetic acid, and ethanolamine.
  • the polymeric compounds contain asymmetric centers. Thus, they can occur as racemates and racemic mixtures, single enantiomers, individual diastereomers, and diastereomeric mixtures. Such isomeric forms are contemplated.
  • Another aspect of this invention relates to a method of treating liver disease or promoting regeneration of liver tissues by administering to a subject in need thereof a pharmaceutical composition obtained by mixing a pharmaceutically acceptable carrier and the isolated preparation described above.
  • Certain polymeric compounds of Formula (I) described above can be obtained from natural sources.
  • certain compounds can be extracted from roots, stems, and leaves of Ericacea (e.g., Boehmeria nivea), Rosaceae, Pinaceae, Vitaceae, or Urticaceae as follows:
  • Dry roots, stems, or leaves of the plant are immersed in water, an organic solvent, a mixture of water and an organic solvent, or a mixture of two or more organic solvents for a predetermined period of time to ensure that a sufficient amount of the desired compound is dissolved.
  • organic solvents include, but are not limited to, methanol, ethanol, propanol, acetone, ethyl acetate, chloroform, dichloromethane, and dimethyl sulfoxide.
  • the above operation can take place at room temperature. Alternatively, it can be performed at elevated temperature.
  • the extracting solvent is refluxed for a certain period to facilitate extracting the desired ingredients from the plant parts.
  • inorganic acid e.g., HCl
  • organic acid e.g., ascorbic acid or tartaric acid
  • inorganic base e.g., Na 2 CO 3 or NaOH
  • organic base e.g., triethylamine
  • a buffer agent e.g., NaH 2 PO 4 or triethylamine hydrochloride
  • NaCl or other salts may be also added to increase the polarity of the extracting solvent.
  • the immersing time varies. It can be 2 hours to 7 days, depending on the extracting solvent and temperature. After the immersing, the solvent is separated from the plant parts and concentrated. The thus-obtained crude extract is further purified.
  • the crude product is first dissolved in polar solvent, such as alcohol, water, or a mixture thereof, the resulting solution is then rinsing with an apolor solvent, e.g., n-hexane, to remove lipid or other apolor substances or rinsing with chloroform or ethyl acetate to remove small phenol compounds, and finally the rinsed solution is concentrated to dryness to afford a partially purified product for use in the above-mentioned treatment.
  • polar solvent such as alcohol, water, or a mixture thereof
  • an apolor solvent e.g., n-hexane
  • chloroform or ethyl acetate to remove small phenol compounds
  • Chromatography technologies include paper chromatography, thin layer chromatography, column chromatography, gas chorography, and liquid chromatography (e.g., high performance liquid chromatography).
  • Suitable eluent solvents include, but are not limited to water, ethanol, methanol, acetone, and a mixture thereof. A gradient eluent system can be used.
  • recrystallization solvent can be an inorganic or organic solvent, e.g., that in which the desired product has a low solubility at a low temperature, but has a higher solubility at a high temperature. It can also be a solvent pair or mixture.
  • the purities of the extract product can be determined by using chromatography or other instruments, such as NMR.
  • a low temperature e.g., ⁇ 40° or ⁇ 0° C.
  • protective gas e.g. nitrogen, argon, or helium.
  • Polymeric compounds in the extract product can be further modified. More specifically, one or more substituents on the compounds can be chemically transformed in order to make other polymeric compounds that can be used to practice this invention.
  • Chemical transformations useful in making such compounds, and chemical reagents and solvents use to perform them are known in the art and include, for example, those described in R. Larock, Comprehensive Organic Transformations , VCH Publishers (1989); T. W. Greene and P. G. M. Wuts, Protective Groups in Organic Synthesis, 2 nd Ed., John Wiley and Sons (1991); L. Fieser and M. Fieser, Fieser and Fieser's Reagents for Organic Synthesis , John Wiley and Sons (1994); and L. Paquette, ed., Encyclopedia of Reagents for Organic Synthesis , John Wiley and Sons (1995) and subsequent editions thereof.
  • An effective amount of the above-obtained pharmaceutically active preparation can be used to improve liver function, treat liver fibrosis, liver cirrhosis, liver inflammation, liver infection, and liver cancer, and regenerate damaged liver tissues.
  • the term “improving a liver function” refers to administering the preparation to a subject, whether or not having liver disease, to enhance his or her liver's capability of metabolism, glycogen storage, decomposition of red blood cells, plasma protein synthesis, hormone production, or detoxification.
  • treating liver disease refers to administering the preparation to a subject who has a condition of liver fibrosis, liver cirrhosis, liver inflammation, liver viral infection (e.g., hepatitis B or C virus infection), or liver cancer, or has a symptom of the condition, or has a predisposition toward the condition, with the purpose to cure, heal, alleviate, relieve, alter, remedy, ameliorate, improve, or affect the condition, the symptoms of the condition, or the predisposition toward the condition.
  • regenerating liver tissues refers to administering the preparation to a subject whose liver has been damaged by disease, alcohol, drugs, or other causes to promote regeneration of liver tissues to reverse the liver damage.
  • an effective amount refers to the amount of the preparation that is required to confer one of the above-described effects on the subject.
  • the effective amount varies, as recognized by those skilled in the art, depending on the types of the effects, route of administration, excipient usage, and the possibility of co-usage with other treatment.
  • a composition containing one or more of the polymeric compounds described above can be administered parenterally, orally, nasally, rectally, topically, or buccally.
  • parenteral refers to subcutaneous, intracutaneous, intravenous, intramuscular, intraarticular, intraarterial, intrasynovial, intrasternal, intrathecal, intralesional, or intracranial injection, as well as any suitable infusion technique.
  • a sterile injectable composition can be a solution or suspension in a non-toxic parenterally acceptable diluent or solvent, such as a solution in 1,3-butanediol.
  • a non-toxic parenterally acceptable diluent or solvent such as a solution in 1,3-butanediol.
  • acceptable vehicles and solvents that can be employed are mannitol and water.
  • fixed oils are conventionally employed as a solvent or suspending medium (e.g., synthetic mono- or diglycerides).
  • Fatty acid, such as oleic acid and its glyceride derivatives are useful in the preparation of injectables, as are natural pharmaceutically acceptable oils, such as olive oil or castor oil, especially in their polyoxyethylated versions.
  • oil solutions or suspensions can also contain a long chain alcohol diluent or dispersant, carboxymethyl cellulose, or similar dispersing agents.
  • a long chain alcohol diluent or dispersant carboxymethyl cellulose, or similar dispersing agents.
  • Other commonly used surfactants such as Tweens or Spans or other similar emulsifying agents or bioavailability enhancers which are commonly used in the manufacture of pharmaceutically acceptable solid, liquid, or other dosage forms can also be used for the purpose of formulation.
  • a composition for oral administration can be any orally acceptable dosage form including capsules, tablets, emulsions and aqueous suspensions, dispersions, and solutions.
  • commonly used carriers include lactose and corn starch.
  • Lubricating agents such as magnesium stearate, are also typically added.
  • useful diluents include lactose and dried corn starch.
  • a nasal aerosol or inhalation composition can be prepared according to techniques well known in the art of pharmaceutical formulation.
  • such a composition can be prepared as a solution in saline, employing benzyl alcohol or other suitable preservatives, absorption promoters to enhance bioavailability, fluorocarbons, and/or other solubilizing or dispersing agents known in the art.
  • a composition having one or more active compounds can also be administered in the form of suppositories for rectal administration.
  • the carrier in the pharmaceutical composition must be “acceptable” in the sense that it is compatible with the active ingredient of the composition (and preferably, capable of stabilizing the active ingredient) and not deleterious to the subject to be treated.
  • One or more solubilizing agents can be utilized as pharmaceutical excipients for delivery of an active compound.
  • examples of other carriers include colloidal silicon oxide, magnesium stearate, cellulose, sodium lauryl sulfate, and D&C Yellow # 10.
  • a compound can be tested by an in vitro or in vivo assay.
  • compounds of this invention can be preliminarily screened by in vitro assays in which the compounds are tested for their bioactivity relating to liver function.
  • Compounds that demonstrate high efficacy in the preliminary screening can be further evaluated by in vivo methods well known in the art to evaluate their activity in treating liver conditions, e.g., liver cancer.
  • Roots and stems of Boehmeria nivea L. Gaud. were washed with water and dried. The dried plant parts were cut into slices having a thickness of 5 mm and stored at 4° C.
  • the slices were grounded and passed through a 20-mesh sieve.
  • the thus-obtained powder was dispersed in 95% ethanol (10 times by weight).
  • the mixture was refluxed for 2 hours twice. After cooled to room temperature, the liquid was collected and centrifuged. The supernatant was condensed under reduced pressure at a temperature below 40° C. and freeze-dried to get a crude product.
  • the slices were grounded and passed through a 20-mesh sieve.
  • the thus-obtained powder was dispersed in reverse osmosis water (10 times by weight).
  • the mixture was refluxed for 2 hours twice.
  • 50%-95% ethanol was added to cause precipitation.
  • the liquid solution was collected and centrifuged.
  • the supernatant was condensed under reduced pressure at a temperature below 40° C. and freeze-dried to obtain a crude product.
  • the crude products obtained from method 1 and method 2 were each dispersed in n-hexane (1:10 w/v) and refluxed using a Soxhlet apparatus for 6 hours to remove lipid. After removal of the solvent, the obtained solid was dissolved in 70% methanol-water solution and 0.3% vitamin C water solution. The solution was condensed under reduced pressure below 40° C., and then an equal volume of chloroform was added. The mixture was placed on an oscillator for 30 minutes. The water layer was separated and ethyl acetate was added. The mixture was oscillated for 30 minutes. The water layer was again separated and condensed under reduced pressure at a temperature below 40° C. and freeze-dried to give a partially purified extract.
  • the crude products obtained from method 1 and method 2 were dissolved in a mixture of water and ethanol (1:10, w/v). n-Hexane (10 times by volume) was added. The mixture was oscillated for 30 minutes to remove lipid. The water layer was separated and ethyl acetate was added. The mixture was oscillated for 30 minutes. The water layer was separated and mixed with n-butanol (1:10 v/v). After oscillation for 30 minutes, the water layer was separated, condensed under reduced pressure at a temperature below 40° C., and freeze-dried to give a partially purified extract.
  • Sample 1 was assessed by X-ray crystallography, NMR, and/Ionization Mass Spectrometry. Compounds of the following structures constituted at least 20% by weight of Sample 1:
  • mice The heterozygous male hepatitis B x (HBx) gene transgenic (HBx-Tg) mouse line A112 of the C57BL/6 background was used.
  • the mice were divided into 6 groups: (A) non-transgenic mice (wild type) mock, (B) non-transgenic mice treated with Sample 1 at the age of 9-20 months old, (C) transgenic mice mock, (D) transgenic mice treated with Sample 1 at the age of 9-20 months old, (E) transgenic mice treated with Sample 1 at the age of 12-20 months old, and (F) transgenic mice treated with Sample 1 at the age of 15-20 months old in this study.
  • Sample 1 was dissolved in distilled water and administered p.o. (1000 mg/kg/day) to the mice using a feeding needle.
  • mice were sacrificed at 20 months old. Liver tissues and sera were collected for pathologic and biochemical analysis.
  • liver weight were measured for each mouse at scarification. The livers were collected, fixed with formalin, and embedded in paraffin. Liver sections were subjected to Hematoxylin and Eosin staining.
  • ALT and AST Alanine aminotransferase assays: Blood samples were collected monthly. Serum ALT and AST values were analyzed by a biochemistry automated analyzer (Hitachi 7080). See Wu et al., Biochemical and Biophysical Research Communications. 2006, 340: 916-928.
  • ICG retention rate test 18 Month-old mice were injected i.v. with ICG (10 mg/dl). Blood samples were collected at 10 minutes after the injection. Serum ICG retention rate was determined using a spectrophotometer at 805 nm.
  • ICG is a substance exclusively cleared from the blood by the liver.
  • the ICG clearance is therefore used as an indicator to evaluate liver function. See Sheng et al., Hepatobiliary Pancreat Dis. Int. 2009, 8:46-49
  • the survival rate of the HBx-Tg mice (Group C) was 64% at the age of 20 months. In contrast, the survival rate of the mice treated with Sample 1 (Group E) was 100% at the age of 20 months. Thus, Sample 1 treatment increased the survival rate of HBx-Tg mice significantly. The results also show that early treatment with Sample 1 improved the survival rate of HBx-Tg mice.
  • the ratio of liver weight to body weight was about 5% in wild type mice (Group A), and increased to 13% in HBx-Tg mice (Group C) at age 20 months old. No significant difference in the ratio was observed between Groups A and Group B. Sample 1 treatment significantly reduced the ratio liver and body weight (about 8%) in Groups D, E and F. These results indicated that Sample 1 reduced HCC progression in HBx transgenic mice.
  • the ICG retention rate of wild type mice was 2.25 ⁇ 0.89 mg/dl
  • the ICG retention rate of wild type mice treated with Sample 1 was 2.13 ⁇ 0.92 mg/dl
  • the ICG retention rate of HBx transgenic mice (4.46 ⁇ 1.17 mg/dl) was significantly higher than wild type mice.
  • the HBx-Tg mice early treated with Sample 1 significantly reduced ICG retention rate (the ICG retention rate was 2.63 ⁇ 0.76 mg/dl for group D and 3.47 ⁇ 0.77 mg/dl for Group E).
  • ALT and AST were significantly increased in HBx-Tg (Group C) after the age of 12 months old.
  • Sample 1 treatment of wildtype mice (Group B) had no any effect on ALT and AST.
  • Sample 1 treatment of mice of HBx-Tg (Groups D and E) at different ages reduced ATL and AST significantly.
  • 8-Week-old Wistar rats were divided into five groups: (A) Na ⁇ ve group (control), (B) diethylnitrosamine (DEN) treated for 6 weeks, (C) DEN and Sample 1 treated for 6 weeks, (D) DEN treated for 9 weeks, and (E) DEN and Sample 1 treated for 9 weeks.
  • DEN in water 100 ppm was administered at 0.02 ml/kg/day for 6 or 9 weeks to induce liver fibrosis and hepatocellular carcinoma (HCC).
  • HCC liver fibrosis and hepatocellular carcinoma
  • the DEN solution was freshly prepared every week. Sample 1 was fed with food at a dose around 1000 mg/kg/day.
  • the rat weights were recorded and liver tissues and sera were collected for the pathologic and biochemical analysis described below.
  • the rats were sacrificed at 6 th , 9 th , or 12 th week.
  • livers were collected, fixed with formalin, and embedded in paraffin. Liver sections were subjected to Hematoxylin and Eosin staining and alpha-smooth muscle actin (a-SMA) immunohistochemistry staining.
  • a-SMA alpha-smooth muscle actin
  • Liver hydroxyproline test 10 mg of liver samples were used to measure the amount of hydroxyproline according to the method described in Lee et al., Journal of Gastroenterology and Hepatology 2005, 20: 1109-1114.
  • 8-Week-old Wistar rats were dived into 6 groups: (A) Na ⁇ ve group, (B) DEN treated for 10.5 weeks, (C) both DEN and Sample 1 treated for 10.5 weeks, (D) DEN treated for 10.5 weeks and Sample 1 treated from weeks 3 to 10.5), (E) DEN treated for 10.5 weeks and Sample 1 treated from weeks 6 to 13.5, and (F) DEN treated for 10.5 weeks and Sample 1 treated from weeks 10.5 to 13.5.
  • DEN in water (50 ppm) was administered at 0.01 ml/kg/day. The DEN solution was freshly prepared every week.
  • Sample 1 was dissolved in distilled water and administered p.o. (1000 mg/kg/day) using a feeding needle.
  • the animals were observed every day until 15 weeks (104 days).
  • the survival rates were analyzed using the nonparametric statistic.
  • Sample 1 increased the survival rate of DEN-induced HCC rats.
  • DEN solution was freshly prepared every week by dissolving a weekly dose of DEN in a volume corresponding to the estimated water consumption of 7 days of drinking water (100 ppm). The weights of the rats were recorded.
  • Sample 1 in distilled water was administered p.o. to two groups of rats (250 mg/kg/day or 1,000 mg/kg/day) using a feeding needle at weeks 6-9. 70% of liver was removed by hepatectomy at week 9. The regenerated liver tissues were collected 2 days after the hepatectomy. The cell mitosis ability of liver sections with Hematoxylin and Eosin staining was analyzed.
  • the liver regeneration rate in the Sample 1-treated groups was significantly increased compared with that of the DEN group (79 ⁇ 6% vs. 32 ⁇ 7%). Reduced food consumption was observed in the DEN group (42 ⁇ 5%) 2 days after hepatectomy, but treatment with SAMPLE 1 recovered the food consumption (83 ⁇ 4%) to the level similar to that of the na ⁇ ve group (91 ⁇ 3%). Food uptake time was longer in the DEN-treated group (27.0 ⁇ 3.3 hrs) compared to the na ⁇ ve group (11.0 ⁇ 1.2 hrs) 2 days after hepatectomy. Treatment with Sample 1 reduced food uptake time to 16.0 ⁇ 2.4 hrs.
  • the Sample 1-treated groups had a survival rate of 100%, while the DEN group had a survival rate of 55% after hepatectomy.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
US12/908,185 2009-12-30 2010-10-20 Liver function and treatment of liver disease Abandoned US20110158933A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US14/574,036 US9474735B2 (en) 2009-12-30 2014-12-17 Liver function improvement and treatment of liver disease

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
TW98145737 2009-12-30
TW098145737A TWI458487B (zh) 2009-12-30 2009-12-30 藥學組合物之用途

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US14/574,036 Division US9474735B2 (en) 2009-12-30 2014-12-17 Liver function improvement and treatment of liver disease

Publications (1)

Publication Number Publication Date
US20110158933A1 true US20110158933A1 (en) 2011-06-30

Family

ID=44187825

Family Applications (2)

Application Number Title Priority Date Filing Date
US12/908,185 Abandoned US20110158933A1 (en) 2009-12-30 2010-10-20 Liver function and treatment of liver disease
US14/574,036 Active US9474735B2 (en) 2009-12-30 2014-12-17 Liver function improvement and treatment of liver disease

Family Applications After (1)

Application Number Title Priority Date Filing Date
US14/574,036 Active US9474735B2 (en) 2009-12-30 2014-12-17 Liver function improvement and treatment of liver disease

Country Status (2)

Country Link
US (2) US20110158933A1 (zh)
TW (1) TWI458487B (zh)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014101366A1 (en) 2012-12-26 2014-07-03 Industrial Technology Research Institute Methods for inhibition of shc-1/p66 to combat aging-related diseases

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5760010A (en) * 1995-01-01 1998-06-02 Klein; Ira Method of treating liver disorders with a macrolide antibiotic
US20050142222A1 (en) * 2003-12-30 2005-06-30 Industrial Technology Research Institute Pharmaceutical mixture for hepatitis treatment and its preparation method
US7371776B2 (en) * 2004-01-30 2008-05-13 Mars, Incorporated Methods and compositions for treating cancer
US20100055065A1 (en) * 2008-09-03 2010-03-04 Miyazaki Prefectural Industrial Support Foundation Agent for inhibiting production of hepatitis c virus and its use
US20100168221A1 (en) * 2008-12-31 2010-07-01 Industrial Technology Research Institute Pharmaceutical composition for treating hepatitis b virus and health food product having hepatitis b virus inhibiting effects
US20130123204A1 (en) * 2008-12-31 2013-05-16 Industrial Technology Research Institute Method for treating hepatitis b

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1452629A (zh) * 2000-05-31 2003-10-29 科学技术振兴事业团 含有人参皂甙Rb1的皮肤组织再生促进剂
CN1443533A (zh) * 2002-03-07 2003-09-24 程彦杰 原花青素类化合物在用于制备解酒保肝产品方面的用途
JP4822291B2 (ja) * 2008-03-14 2011-11-24 財団法人宮崎県産業支援財団 肝線維化抑制剤
CN101822372A (zh) 2009-03-05 2010-09-08 财团法人工业技术研究院 用以治疗b型肝炎的药学组合物与抑制b型肝炎病毒的保健食品

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5760010A (en) * 1995-01-01 1998-06-02 Klein; Ira Method of treating liver disorders with a macrolide antibiotic
US20050142222A1 (en) * 2003-12-30 2005-06-30 Industrial Technology Research Institute Pharmaceutical mixture for hepatitis treatment and its preparation method
US7371776B2 (en) * 2004-01-30 2008-05-13 Mars, Incorporated Methods and compositions for treating cancer
US20100055065A1 (en) * 2008-09-03 2010-03-04 Miyazaki Prefectural Industrial Support Foundation Agent for inhibiting production of hepatitis c virus and its use
US20100168221A1 (en) * 2008-12-31 2010-07-01 Industrial Technology Research Institute Pharmaceutical composition for treating hepatitis b virus and health food product having hepatitis b virus inhibiting effects
US20130123204A1 (en) * 2008-12-31 2013-05-16 Industrial Technology Research Institute Method for treating hepatitis b

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Chang et al., "The Anti-hepatitis B Virus Activity of Boehmeria nivea Extract in HBV-viremia SCID Mice" eCAM 2010; 7 (2) 189-195, Advance Access Publication 7 January 2008. *
Czochanska et al. ("Polymeric proanthocyanidins. Stereochemistry, structural units, and molecular weight, Journal of the Chemical Society, 1980, (10), 2278-2286). *
Sugimoto et al. (J Hepatobiliary Pancreat Surg 2006: 13: 543-548). *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014101366A1 (en) 2012-12-26 2014-07-03 Industrial Technology Research Institute Methods for inhibition of shc-1/p66 to combat aging-related diseases

Also Published As

Publication number Publication date
TWI458487B (zh) 2014-11-01
TW201121557A (en) 2011-07-01
US20150133539A1 (en) 2015-05-14
US9474735B2 (en) 2016-10-25

Similar Documents

Publication Publication Date Title
JP5670335B2 (ja) ベンダムスチン液体製剤
US10881678B2 (en) Cytotoxic agents for the treatment of cancer
CN103403552B (zh) 治疗癌症的方法
TWI778949B (zh) 含有青蒿琥酯的組合物
EP2931042B1 (en) Anthracycline formulations
EP2046317B1 (en) Compositions and methods of reducing tissue levels of drugs when given as orotate derivatives
AU2023305443A1 (en) Preparation of stable psilocin salts, esters and conjugates and uses thereof
US9474735B2 (en) Liver function improvement and treatment of liver disease
EP2689777B1 (en) Pharmaceutical composition for inducing hepatic regeneration
AU2020346898A1 (en) Phospholipid ether conjugates as cancer-targeting drug vehicles
EP4267191A1 (en) Compositions comprising exon skipping oligonucleotide conjugates for treating muscular dystrophy
KR102270619B1 (ko) 고분자화 약물 함유 약제학적 조성물
JP6305422B2 (ja) 老化関連疾患を克服するためにｓｈｃ−１／ｐ６６を抑制する方法
CN114558004B (zh) Qtx125药物制剂
KR102467932B1 (ko) 간을 표적으로 하는 특정 리간드와 갑상선 호르몬 수용체 작용제를 포함하는 약물
US10137159B2 (en) Boehmeria extract and its use in treating liver diseases
JP5842367B2 (ja) 抗癌剤増感剤
JP2011001273A (ja) ｅＭＩＰを有効成分とする水溶性製剤

Legal Events

Date Code Title Description
STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION